Stay updated on Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.

Latest updates to the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 13, 2025, while a date for March 25, 2025, has been removed.SummaryDifference1.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check81 days agoChange DetectedThe page has been updated to reflect a new completion status and a future date of February 13, 2025, while removing the previous status of being active but not recruiting and a date of April 5, 2024.SummaryDifference2%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference6%
Stay in the know with updates to Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.